SIRPA and neoplasm: To investigate the impact of tumor neovascularization on tumor growth and the potential interference with the anti-tumor effect of CD47 blockade within the tumor immune microenvironment, Hu-PDX models were subjected to the administration of SIRPα-Fc and VEGFR1-Fc, aiming to achieve a simultaneous blockade of CD47 and tumor angiogenesis.